Assessing the use of antiviral treatment to control influenza

Epidemiology and Infection

Volumn 760, Issue , 2014, Pages 1621-1631

  Kramer, S C ^a   Bansal, S ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antiviral drugs; control; infectious disease epidemiology; influenza; influenza vaccines

Indexed keywords

ANTIVIRUS AGENT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; TRIVALENT INACTIVATED VIRUS VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ANTIVIRAL THERAPY; ARTICLE; CONSERVATIVE TREATMENT; DRUG EFFICACY; DRUG USE; EPIDEMIC; INFECTION CONTROL; SEASONAL INFLUENZA; URBAN POPULATION; VACCINATION; VIRUS TRANSMISSION; ADOLESCENT; ADULT; AGED; CHILD; DISEASE OUTBREAKS; HUMAN; INFLUENZA, HUMAN; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; THEORETICAL MODEL; TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; MODELS, THEORETICAL; YOUNG ADULT;

EID: 84929166440     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268814002520     Document Type: Article

References (40)

1. Chowell G, Miller MA, Viboud C. Seasonal influenza in the United States, France, and Australia: transmission and prospects for control. Epidemiology and Infection 2008; 136: 852-864
2. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly Report. Recommendations and Reports 2010; 59: 1-62
3. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25: 6852-6862
4. Wood JM. Developing vaccines against pandemic influenza. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 2001; 356: 1953-1960
5. Osterholm MT, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-Analysis. Lancet Infectious Diseases 2012; 12: 36-44
6. Osterholm MT, et al. The compelling need for gamechanging influenza vaccines: an analysis of the influenza vaccine enterprise and recommendations for the future. Minneapolis: Center for Infectious Disease Research and Policy, 2012. Sponsored by the Alfred P. Sloan Foundation. (http://www.cidrap.umn.edu/sites/default/files/public/downloads/ccivi-report.pdf).
7. Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Recommendations and Reports 2011; 60: 1-24
8. Nicholson KG, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 2000; 355: 1845-1850
9. Goldstein E, et al. Oseltamivir for treatment and prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009. BMC Infectious Diseases. Published online: 20 July 2009. doi:10.1186/1471-2334-10-211.
10. Halloran ME, et al. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. American Journal of Epidemiology 2007; 165: 212-221
11. Ng S, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clinical Infectious Diseases 2010; 50: 707-714
12. Pebody RG, et al. Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. Emerging Infectious Diseases 2011; 17: 990-999
13. Carrat F, et al. A small-world-like model for comparing interventions aimed at preventing and controlling influenza pandemics. BMC Medicine. Published online: 23 October 2006. doi:10.1186/1741-7015-4-26.
14. Ferguson NM, et al. Strategies for mitigating an influenza pandemic. Nature 2006; 442: 448-452
15. Pepin KM, Riley S, Grenfell BT. Effects of influenza antivirals on individual and population immunity over many epidemic waves. Epidemiology and Infection 2013; 141: 366-376
16. Longini Jr. IM, et al. Containing pandemic influenza with antiviral agents. American Journal of Epidemiology 2004; 159: 623-633
17. Black AJ, et al. Epidemiological consequences of household-based antiviral prophylaxis for pandemic influenza. Journal of the Royal Society Interface. Published online: 6 February 2013. doi:10.1098/rsif.2012.1019.
18. Bansal S, Pourbohloul B, Meyers LA. A comparative analysis of influenza vaccination programs. PLoS Medicine 2006; 3: 1816-1825
19. Meyers LA, et al. Network theory and SARS: predicting outbreak diversity. Journal of Theoretical Biology 2005; 232: 71-81
20. Bansal S, et al. The shifting the demographic landscape of pandemic influenza. PLoS ONE. Published online: 26 February 2010. doi:10.1371/journal.pone.0009360.
21. Frost WH. Statistics of influenza morbidity: with special reference to certain factors in case incidence and case fatality. Public Health Reports 1920; 36: 584-597
22. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 2004; 432: 904-906
23. Yang Y, et al. The transmissibility and control of pandemic influenza A (H1N1) virus. Science 2009; 326: 729-733
24. Simpson CR, et al. Effectiveness of H1N1 vaccine for the prevention of pandemic influenza in Scotland, UK: a retrospective observational cohort study. Lancet Infectious Diseases 2012; 12: 696-702
25. Centers for Disease Control and Prevention. Final estimates for 2009-10 seasonal influenza and influenza A (H1N1) 2009 monovalent vaccination coverage-United States, August 2009 through May, 2010 Atlanta: CDC, 2011 (http://www.cdc.gov/flu/professionals/vaccination/coverage-0910estimates.htm). Accessed 7 August 2013.
26. Ng S, et al. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. Journal of Infectious Diseases 2013; 208: 1320-1324
27. Allard A, et al. Heterogeneous bond percolation on multitype networks with an application to epidemic dynamics. Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics. doi:10.1103/PhysRevE.79.036113. Published online: March 2009.
28. Centers for Disease Control and Prevention. Selfreported influenza vaccination coverage trends 1989-2008 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States, National Health Interview Survey (NHIS) [Table] Atlanta: CDC (updated 26 September 2012) (http://www.cdc.gov/flu/fluvaxview/trends.htm). Accessed 7 August 2013.
29. Atkins CY, et al. Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Emerging Infectious Diseases 2011; 17: 1591-1598
30. Yoshida M, et al. Seasonal influenza surveillance using prescription data for anti-influenza medications. Japanese Journal of Infectious Diseases 2009; 62: 233-235
31. Cowling BJ, et al. Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. Clinical Infectious Diseases 2012; 55: 695-702
32. Cowling BJ, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clinical Infectious Diseases 2010; 51: 1370-1379
33. Viboud C, Simonsen L. Does seasonal influenza vaccination increase the risk of illness with the 2009 A/H1N1 pandemic virus? PLoS Medicine. Published online: 6 April 2010. doi:10.1371/journal. pmed.1000259.
34. Moghadas SM, et al. Population-wide emergence of antiviral resistance during pandemic influenza. PLoS ONE. Published online: 19 March 2008. doi:0.1371/journal.pone.0001839
35. Longini IM Jr., Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. American Journal of Epidemiology 2005; 161: 303-306
36. Medlock J, Galvani AP. Optimizing influenza vaccine distribution. Science 2009; 325: 1705-1708
37. van den Dool C, et al. The effects of influenza vaccination of health care workers in nursing homes: insights from a mathematical model. PLoS Medicine. Published online: 28 October 2008. doi:10.1371/journal.pmed. 0050200.
38. Biggerstaff M, et al. Self-reported influenza-like illness and receipt of influenza antiviral drugs during the 2009 pandemic, United States, 2009-2010 American Journal of Public Health. Published online: October 2012. doi:10.2105/ajph.2012.300651.
39. National Institute of Infectious Diseases. Antiviral resistance surveillance in Japan (as of 16 June 2014). Tokyo: NIID (updated 16 June 2014) (http://www.nih.go.jp/niid/en/influ-resist-e/4751-flu-dr-e20140616.html). Accessed 11 July 2014.
40. Chao DL. Modelling the global transmission of antiviral-resistant influenza viruses. Influenza and Other Respiratory Viruses 2013; 7: 58-62